Wockhardt’s Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate...

India’s ‘blockbuster’ drugs to take on deadly superbugs   Antibiotics are hailed as medical saviours. But they are increasingly facing a crafty adversary: bacteria that mutate and adapt and...